Valuation: Daxor Corporation

Market Cap 60.14M 52.82M 48.67M 45.51M 85.35M 5.67B 86.92M 584M 226M 2.8B 226M 221M 9.72B P/E 2026 *
-49.1x
P/E 2027 * -344x
Enterprise Value 60.14M 52.82M 48.67M 45.51M 85.35M 5.67B 86.92M 584M 226M 2.8B 226M 221M 9.72B EV / Sales 2026 *
5.05x
EV / Sales 2027 * 2.89x
Free-Float
47.22%
Yield 2026 *
-
Yield 2027 * -
1 week+5.85%
Current month+0.39%
3 months-0.67%
6 months-25.34%
Current year-30.03%
1 week 9.5
Extreme 9.5
10.65
1 month 9.26
Extreme 9.26
11.16
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Change 5-day change 1-year change 3-year change Capi.($)
-1.71%-2.64%+9.90%+7.50% 60.14M
+1.07%-4.78%+18.87%+104.45% 14.45B
+1.38%-12.52%+49.35%+139.82% 11.69B
-0.66%-2.76%-2.56%+39.28% 8.82B
+0.43%+0.80%-12.39%-11.88% 7.6B
+1.25%-8.06%+31.22%+121.97% 7.36B
+0.38%-2.43%+4.74%+52.81% 6.33B
-0.26%+1.61%+7.85%+35.73% 4.61B
+0.55%+1.78%+11.36%+7.51% 4.1B
-1.64%-6.71% - - 3.71B
Average +0.28%-4.18%+13.15%+55.24% 7.63B
Weighted average by Cap. +0.53%-5.33%+16.55%+74.25%

Financials

2026 *2027 *
Net sales 11.9M 10.45M 9.63M 9M 16.89M 1.12B 17.2M 116M 44.76M 554M 44.69M 43.71M 1.92B 20.8M 18.27M 16.83M 15.74M 29.52M 1.96B 30.06M 202M 78.23M 968M 78.11M 76.4M 3.36B
Net income -1.2M -1.05M -971K -908K -1.7M -113M -1.73M -11.65M -4.51M -55.82M -4.51M -4.41M -194M -200K -176K -162K -151K -284K -18.87M -289K -1.94M -752K -9.3M -751K -735K -32.33M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
26-06-25 $10.32 -1.71% 551
26-06-24 $10.50 +3.50% 8,412
26-06-23 $10.14 +6.79% 2,812
26-06-22 $9.500 -2.56% 1,126
26-06-18 $9.750 +3.70% 3,570
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.32USD
Average target price
22.50USD
Spread / Average Target
+118.02%

Quarterly revenue - Rate of surprise